Safety outcomes following COVID-19 vaccination and infection in 5.1 million children in England

Emma Copland; Martina Patone; Defne Saatci; Lahiru Handunnetthi; Jennifer Hirst; David P. J. Hunt; Nicholas L. Mills; Paul Moss; Aziz Sheikh; Carol A. C. Coupland; Anthony Harnden; Chris Robertson; Julia Hippisley-Cox

doi:10.1038/s41467-024-47745-z

Safety outcomes following COVID-19 vaccination and infection in 5.1 million children in England

Emma Copland, Martina Patone, Defne Saatci, Lahiru Handunnetthi, Jennifer Hirst, David P. J. Hunt, Nicholas L. Mills, Paul Moss, Aziz Sheikh, Carol A. C. Coupland, Anthony Harnden, Chris Robertson, Julia Hippisley-Cox^*

^*Corresponding author for this work

Immunology and Immunotherapy

Research output: Contribution to journal › Article › peer-review

23 Downloads (Pure)

Abstract

The risk-benefit profile of COVID-19 vaccination in children remains uncertain. A self-controlled case-series study was conducted using linked data of 5.1 million children in England to compare risks of hospitalisation from vaccine safety outcomes after COVID-19 vaccination and infection. In 5-11-year-olds, we found no increased risks of adverse events 1–42 days following vaccination with BNT162b2, mRNA-1273 or ChAdOX1. In 12-17-year-olds, we estimated 3 (95%CI 0–5) and 5 (95%CI 3–6) additional cases of myocarditis per million following a first and second dose with BNT162b2, respectively. An additional 12 (95%CI 0–23) hospitalisations with epilepsy and 4 (95%CI 0–6) with demyelinating disease (in females only, mainly optic neuritis) were estimated per million following a second dose with BNT162b2. SARS-CoV-2 infection was associated with increased risks of hospitalisation from seven outcomes including multisystem inflammatory syndrome and myocarditis, but these risks were largely absent in those vaccinated prior to infection. We report a favourable safety profile of COVID-19 vaccination in under-18s.

Original language	English
Article number	3822
Journal	Nature Communications
Volume	15
Issue number	1
DOIs	https://doi.org/10.1038/s41467-024-47745-z
Publication status	Published - 27 May 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41467-024-47745-zLicence: Creative Commons: Attribution (CC BY)

CoplandE2024SafetyFinal published version, 768 KBLicence: Creative Commons: Attribution (CC BY)

1 Comment/debate

Author Correction: Safety outcomes following COVID-19 vaccination and infection in 5.1 million children in England
Copland, E., Patone, M., Saatci, D., Handunnetthi, L., Hirst, J., Hunt, D. P. J., Mills, N. L., Moss, P., Sheikh, A., Coupland, C. A. C., Harnden, A., Robertson, C. & Hippisley-Cox, J., 8 Jul 2024, In: Nature Communications. 15, 1, 5723.
Research output: Contribution to journal › Comment/debate

Open Access
File

9 Downloads (Pure)

Cite this

Copland, E., Patone, M., Saatci, D., Handunnetthi, L., Hirst, J., Hunt, D. P. J., Mills, N. L., Moss, P., Sheikh, A., Coupland, C. A. C., Harnden, A., Robertson, C., & Hippisley-Cox, J. (2024). Safety outcomes following COVID-19 vaccination and infection in 5.1 million children in England. Nature Communications, 15(1), Article 3822. https://doi.org/10.1038/s41467-024-47745-z

@article{1d140f0d635b40abbcc42f81e1569bb5,

title = "Safety outcomes following COVID-19 vaccination and infection in 5.1 million children in England",

abstract = "The risk-benefit profile of COVID-19 vaccination in children remains uncertain. A self-controlled case-series study was conducted using linked data of 5.1 million children in England to compare risks of hospitalisation from vaccine safety outcomes after COVID-19 vaccination and infection. In 5-11-year-olds, we found no increased risks of adverse events 1–42 days following vaccination with BNT162b2, mRNA-1273 or ChAdOX1. In 12-17-year-olds, we estimated 3 (95%CI 0–5) and 5 (95%CI 3–6) additional cases of myocarditis per million following a first and second dose with BNT162b2, respectively. An additional 12 (95%CI 0–23) hospitalisations with epilepsy and 4 (95%CI 0–6) with demyelinating disease (in females only, mainly optic neuritis) were estimated per million following a second dose with BNT162b2. SARS-CoV-2 infection was associated with increased risks of hospitalisation from seven outcomes including multisystem inflammatory syndrome and myocarditis, but these risks were largely absent in those vaccinated prior to infection. We report a favourable safety profile of COVID-19 vaccination in under-18s.",

author = "Emma Copland and Martina Patone and Defne Saatci and Lahiru Handunnetthi and Jennifer Hirst and Hunt, {David P. J.} and Mills, {Nicholas L.} and Paul Moss and Aziz Sheikh and Coupland, {Carol A. C.} and Anthony Harnden and Chris Robertson and Julia Hippisley-Cox",

year = "2024",

month = may,

day = "27",

doi = "10.1038/s41467-024-47745-z",

language = "English",

volume = "15",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Springer",

number = "1",

}

TY - JOUR

T1 - Safety outcomes following COVID-19 vaccination and infection in 5.1 million children in England

AU - Copland, Emma

AU - Patone, Martina

AU - Saatci, Defne

AU - Handunnetthi, Lahiru

AU - Hirst, Jennifer

AU - Hunt, David P. J.

AU - Mills, Nicholas L.

AU - Moss, Paul

AU - Sheikh, Aziz

AU - Coupland, Carol A. C.

AU - Harnden, Anthony

AU - Robertson, Chris

AU - Hippisley-Cox, Julia

PY - 2024/5/27

Y1 - 2024/5/27

N2 - The risk-benefit profile of COVID-19 vaccination in children remains uncertain. A self-controlled case-series study was conducted using linked data of 5.1 million children in England to compare risks of hospitalisation from vaccine safety outcomes after COVID-19 vaccination and infection. In 5-11-year-olds, we found no increased risks of adverse events 1–42 days following vaccination with BNT162b2, mRNA-1273 or ChAdOX1. In 12-17-year-olds, we estimated 3 (95%CI 0–5) and 5 (95%CI 3–6) additional cases of myocarditis per million following a first and second dose with BNT162b2, respectively. An additional 12 (95%CI 0–23) hospitalisations with epilepsy and 4 (95%CI 0–6) with demyelinating disease (in females only, mainly optic neuritis) were estimated per million following a second dose with BNT162b2. SARS-CoV-2 infection was associated with increased risks of hospitalisation from seven outcomes including multisystem inflammatory syndrome and myocarditis, but these risks were largely absent in those vaccinated prior to infection. We report a favourable safety profile of COVID-19 vaccination in under-18s.

AB - The risk-benefit profile of COVID-19 vaccination in children remains uncertain. A self-controlled case-series study was conducted using linked data of 5.1 million children in England to compare risks of hospitalisation from vaccine safety outcomes after COVID-19 vaccination and infection. In 5-11-year-olds, we found no increased risks of adverse events 1–42 days following vaccination with BNT162b2, mRNA-1273 or ChAdOX1. In 12-17-year-olds, we estimated 3 (95%CI 0–5) and 5 (95%CI 3–6) additional cases of myocarditis per million following a first and second dose with BNT162b2, respectively. An additional 12 (95%CI 0–23) hospitalisations with epilepsy and 4 (95%CI 0–6) with demyelinating disease (in females only, mainly optic neuritis) were estimated per million following a second dose with BNT162b2. SARS-CoV-2 infection was associated with increased risks of hospitalisation from seven outcomes including multisystem inflammatory syndrome and myocarditis, but these risks were largely absent in those vaccinated prior to infection. We report a favourable safety profile of COVID-19 vaccination in under-18s.

U2 - 10.1038/s41467-024-47745-z

DO - 10.1038/s41467-024-47745-z

M3 - Article

SN - 2041-1723

VL - 15

JO - Nature Communications

JF - Nature Communications

IS - 1

M1 - 3822

ER -

Safety outcomes following COVID-19 vaccination and infection in 5.1 million children in England

Abstract

UN SDGs

Access to Document

Fingerprint

Research output

Author Correction: Safety outcomes following COVID-19 vaccination and infection in 5.1 million children in England

Cite this